Cirsilineol inhibits the proliferation and migration of endometriotic cells

Xumeng Gu¹, Tianchan Zhang¹, Tongtong Liu², Huifang Cong¹, Wenpeng Wu³*
¹Department of Gynaecology Ward 1, The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang Province 150001, ²Department of Gynecology and Obstetrics Ward, The Third Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang Province 150040, ³Department of Acupuncture Ward 3, The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang Province 150001, China

*For correspondence: Email: wuwenpeng3080701@163.com; Tel: +86-0451-87090221

Sent for review: 30 August 2023 Revised accepted: 25 November 2023

Abstract

Purpose: To determine the effect of cirsilineol on the proliferation and migration of endometriotic cells.

Methods: Human endometriotic epithelial cells 12Z were treated with 5, 10 and 20 μM cirsilineol, respectively. Cell proliferation was evaluated using BrdU incorporation assay whereas wound healing assay was used to investigate cell migration, and cell invasion was assessed by Transwell assay. Cell cycle was investigated using flow cytometry while protein expression and phosphorylation levels of p65 and IκBα were evaluated by Western blot.

Results: Treatment with cirsilineol at either 10 μM or 20 μM resulted in a significant reduction in cell proliferation and cell cycle arrest at the G2/M phase (p < 0.05). Moreover, cirsilineol weakened cell migration and invasion in 12Z cells, but did not alter the expression of p65. However, it significantly downregulated the phosphorylation of p65 and increased the expression of IκBα, while attenuating the phosphorylation level of IκBα (p < 0.05). Furthermore, 5 μM cirsilineol did not show any significant effects on these cellular activities, suggesting the activity of cirsilineol in 12Z cells is dose-dependent.

Conclusion: Cirsilineol inhibits cell proliferation, induces cell cycle arrest, suppresses migration and invasion of endometriotic epithelial cells by regulating NF-κB pathway. Thus, cirsilineol might be a potential therapeutic candidate for endometriosis treatment.

Keywords: Cirsilineol, Cell migration, Cell proliferation, Endometriotic cells, NF-κB pathway

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.


INTRODUCTION

Endometriosis is a challenging condition marked by the occurrence of endometrial cells located outside the confines of uterine cavity. There are at least 176 million women with this disorder worldwide. It often leads to pelvic pain, and up to 50 % of patients also experience fertility issues [1]. Despite its prevalence, the exact cause and underlying mechanisms of endometriosis remain unknown. While the leading hypothesis attributes the condition to retrograde menstruation transporting endometrial fragments into the pelvic cavity, other factors also contribute to the progress of ectopic lesions. These factors involve processes that alter the viability, proliferation,
adhesion, neovascularization, and migration of reversed endometrial fragments and cells; hence the need further research to fully comprehend the molecular mechanisms [2].

A potential factor in endometriosis pathogenesis is the constitutive activation of nuclear factor kappa B (NF-κB) observed in endometriotic cells [3]. Specifically, the expression of NF-κB p65 is increased when women experiencing advanced endometriosis, suggesting a critical role for NF-κB signaling in the disease. NF-κB is known to regulate various genes associated with cell proliferation, apoptosis, inflammation, migration, invasion, and angiogenesis [4].

In the realm of traditional medicine, the herbal remedies from Chinese and African traditions are gaining increased attention. Cirsilineol, a flavonoid bioactive compound found in Artemisia vestita wall, has shown potent properties such as antioxidant, antibacterial, hypnotic, antineoplastic, and sedative effects. It has also exhibited cytotoxicity against various cancer cells and has been found to attenuate particulate matter 2.5 (PM 2.5)-induced lung injury in mice [5]. Additionally, cirsilineol exerts inhibitory effects on the migration and invasion of prostate cancer cells, and has been observed to suppress NF-κB signaling protein expression, thereby exhibiting anti-inflammatory properties [6,7].

The role of cirsilineol in endometriosis however remains unclear, and therefore, requires further investigation. Studies on its potential effects on endometriosis pathophysiology would shed light on new therapeutic avenues for managing this complex and enigmatic condition.

**EXPERIMENTAL**

**Cell culture**

Epithelial endometriotic cell line 12Z was maintained in Dulbecco’s Modified Eagle Medium, and added to 10 % fetal bovine serum (FBS) in a 37 °C incubator in an atmosphere of 5 % CO₂. Approximately 10⁶ cells were seeded in a 6-well plate; 12 h later, the cells were treated with cirsilineol (PHL82500, Millipore Sigma, Burlington, MA, USA) at concentrations of 5, 10 and 20 μM, respectively.

**5-bromo-2′-deoxyuridine (BrdU) proliferation assay**

The 12Z cells treated with 5, 10 and 20 μM cirsilineol were labeled with 50 μM BrdU for 30 min in 96-well plate. The cells fixed with 4 % paraformaldehyde (PFA) for 15 min and permeabilized with 0.5 % Triton X-100 for 15 min at room temperature. Next, the cells were incubated with blocking buffer (1 % bull serum albumin in PBS) for 1 h, followed by anti-BrdU antibody (ab8152, Abcam, Cambridge, UK; 1:200) for 1 h. After washing twice with PBS, the cells were incubated with horseradish peroxidase (HRP) conjugated goat anti-mouse IgG (31160, Thermo Fisher, Waltham, MA, USA; 1:1000) for 1 h at room temperature. Furthermore, the washed cells were incubated with 100 μl TMB substrate at room temperature for 5 min and then replaced with 100 μl stop solution. The absorbance of each well was measured under a microplate reader (Microplate Reader 550; Bio-Rad, Hercules, CA, USA) at 450 nm.

**Cell cycle analysis**

Flow cytometry was performed to quantify the cell counts at G1, G2/M and S phases. The 12Z cells treated with 5, 10 and 20 μM cirsilineol were harvested for cell cycle analysis using flow cytometry. The single cell suspension was centrifuged at 200 g for 5 min, and the cell pellet was fixed with 4 % PFA for 30 min. The cell samples were incubated with 20 μg/ml RNaseA at 37 °C for 30 min, washed once with PBS and then stained with 50 μg/ml propidium iodide (PI) for 30 min at room temperature. The PI-stained cells were analyzed using flow cytometry (BD LSR II; BD Bioscience, Franklin Lakes, NJ, USA) and the cell cycle was analyzed using FlowJo software.

**Transwell assay**

The 12Z cells treated with 5, 10 and 20 μM cirsilineol were seeded in the upper chamber above the membrane inserts of Transwell plates (P80201250; Merck, Darmstadt, Germany). Matrigel (E1270; Sigma Aldrich, Shanghai, China) was applied to the upper compartment for invasion assay. The lower chamber contained medium with 10 % FBS, while the upper chamber was filled with serum-free medium. After incubation at 37 °C for 48 h, cells that migrated through the membrane were fixed with 4 % PFA and stained with 1 % crystal violet. At least 10 randomly selected fields were assessed for each sample, and the mean counts of stained cells were quantified using ImageJ software (National Institutes of Health, USA).

**Wound healing assay**

The 12Z cells treated with 5, 10 and 20 μM cirsilineol were seeded into a 6-well plate, and after the cells were attached to the bottom, the cell layer was scratched using a pipette tip as
previously described [8]. The cells were imaged at the scratching scope, and the width of the scratch line was measured using ImageJ software.

**Western blot assay**

The total protein of 5, 10 and 20 μM cirsilineol-treated 12Z cells were homogenized in lysis buffer (25 mM Tris-HCl pH 7.5, 200 mM NaCl, 50 mM KCl, 0.5 % sodium deoxycholate, 10 % Glycerol, 0.1 % SDS, 1 % NP-40). After 10,000 g centrifuging at 4 for 10 min, the supernatant was mixed with loading buffer and boiled for 10 min. The samples were subjected SDS-PAGE gel separation and transferred to nitrocellulose membrane. Then the membrane was incubated with the primary antibodies at 4℃ overnight.

The antibodies used are p65 (10745-1-AP, ProteinTech, IL, USA; 1:500), phosphorylated p65 (p-p65) (82335-1-RR, ProteinTech; 1:4000), phosphorylated IkBa (p-IkBa) (80455-01-RR, ProteinTech; 1:2000), IkBa (10268-1-AP, ProteinTech; 1:8000) and β-actin (82349-1-RR, ProteinTech; 1:5000). They were then incubated with HRP-labeled with anti-rabbit IgG (B900210, ProteinTech; 1:5000) at room temperature for 1 h. The target bands were visualized with ECL reagents (Solarbio, Beijing, China), and the relative intensity was determined by ImageJ software and normalized to β-actin [9].

**Quantification and statistical analysis**

Data of three biological replicates are presented as mean ± standard deviation (SD), the figures were drawn using GraphPad Prism 8.0 (Dotmatics, Boston, MA, USA) and the differences between any two groups were calculated by unpaired t-test. \( P < 0.05 \) was considered significant differences.

**Cirsilineol inhibits proliferation of endometriotic epithelial cells**

The chemical structure of cirsilineol is shown in Figure 1 A. The BrdU proliferation assay in 12Z cells revealed that cirsilineol negatively regulated cell proliferation. There was a reduction in absorbance in 5 μM cirsilineol-treated cells (\( p < 0.05 \)). When the concentration of cirsilineol increased to 10 or 20 μM, cell growth significantly decreased compared to the cirsilineol-free group (0 μM cirsilineol; Figure 1 B). Therefore, cirsilineol attenuated the proliferation of endometriotic epithelial cells in a dose-dependent manner.

**Cirsilineol induced cell cycle arrest in endometriotic epithelial cells**

Cell cycle is tightly involved in cell proliferation regulation, and hence it was necessary to study the cell cycle in cirsilineol-treated cells. Specifically, the variation of cell cycle mainly occurred at G1 and G2/M phases, but no difference was observed at S phase. Compared to control group (0 μM cirsilineol), no significant difference was observed in 12Z cells treated with 5 μM cirsilineol (\( p < 0.05 \)). When the cells were treated with 10 or 20 μM cirsilineol, there was a significant reduction in cell counts at G1 phase, and increase at G2/M phase (Figure 2). The data showed that cirsilineol arrested cell cycle at G2/M phase in a dose-dependent manner.

**Figure 1:** Cirsilineol inhibits the proliferation of endometriotic epithelial cells. (A) Chemical structure of cirsilineol; (B) Effect of cirsilineol on the proliferation of 12Z cells. Error bar, mean ± SD (n = 3); *** \( p < 0.001 \)

**Figure 2:** Cirsilineol induces cell cycle arrest in endometriotic epithelial cells. Cell counts at G1, G2/M and S. Error bar, mean ± SD (n = 3); * \( p < 0.05 \); ** \( p < 0.01 \)
Cirsilineol suppresses the migration and invasion of endometriotic epithelial cells

The wound healing assay revealed larger scratches were left in 12Z cells treated with 10 or 20 μM Cirsilineol than the control group, indicating that Cirsilineol weakened cell migration (Figure 3 A). The number of 12Z cells that passed through the membrane insert was reduced in 10 or 20 μM cirsilineol-treated cells, but no reduction was observed in 5 μM cirsilineol-treated cells (Figure 3 C). There was no significant difference in the 5 μM cirsilineol group compared to the control group, but the difference was significant in the 10 or 20 μM cirsilineol group (Figure 3 D; p < 0.05). Thus, cirsilineol inhibited the migration and invasion of endometriotic epithelial cells.

![Figure 3: Cirsilineol suppressed migration and invasion of endometriotic epithelial cells. (A) Remaining scratch width in cirsilineol-treated 12Z cells; (B) Scratch width; (C) Invasion of 12Z cells treated with cirsilineol; (D) Invasion cells. Error bar, mean ± SD (n =3); *** p < 0.001](image)

Cirsilineol inhibits NF-κB pathway

The results obtained showed that 10 or 20 μM cirsilineol downregulated the phosphorylation of p65, but did not affect p65 expression. Furthermore, cirsilineol at the concentration of (10 or 20 μM concentration) enhanced the expression of IκBα, while decreasing IκBα phosphorylation level (Figure 4). Therefore, cirsilineol inhibited NF-κB pathway by reducing p65 and IκBα phosphorylation.

![Figure 4: Cirsilineol inhibits NF-κB pathway. Protein expression and phosphorylation level of p65 and IκBα in cirsilineol-treated 12Z cells. Error bar, mean ± SD; **p < 0.01, ***p < 0.001](image)

DISCUSSION

Endometriosis is a chronic and often debilitating gynecological disorder affecting millions of women worldwide.
significant dose-dependent decrease in cell proliferation rates.

Inhibition of migration and invasion are critical aspects of controlling endometriotic lesion growth and spread. Uncontrolled migration and invasion of endometriotic epithelial cells into surrounding tissues are responsible for the formation of ectopic lesions, leading to chronic inflammation, pain, and infertility in the affected women [14]. The findings of this study demonstrate that cirsilineol curtailed the migration and invasion of endometriotic epithelial cells, offering a potential strategy for countering the progression of endometriotic lesions. The inhibitory effects of cirsilineol on cellular movement and invasion are crucial in preventing the establishment of new lesions and restricting the expansion of existing ones [15].

In this study, cirsilineol's inhibitory effects on the migration and invasion of endometriotic epithelial cells present some evidence for its potential as a novel therapeutic approach for endometriosis. By impeding cellular motility and invasion, cirsilineol offers a means of controlling the progression of endometriotic lesions and alleviate the burden of this chronic condition on affected individuals. However, further preclinical and clinical investigations are necessary to fully explore the molecular mechanisms involved, and to determine the safety and efficacy of Cirsilineol as a potential treatment for endometriosis.

NF-κB is reported to be closely associated with cell proliferation, apoptosis, migration, invasion, and angiogenesis. NF-κB activating proteins enhance the proliferation, migration, invasion, and reduction in radiation sensitivity of gastric cancer cells [16]. NF-κB signaling pathway was deactivated in endometriosis, which functions by inhibiting the proliferation, migration, invasion and inflammation of endometrial stromal cells [17]. Prior research suggests the persistent activation of NF-κB in endometriotic cells. Elevated nuclear expression of NF-κB p65 is observed in the eutopic endometrium of women experiencing advanced endometriosis, suggesting a critical role for NF-κB signaling in the disease [18]. The western blot data in this work suggested that the protein expression or phosphorylation level of two key molecules, p65 and IκBα, were reduced in cirsilineol-treated cells. This demonstrates that NF-κB pathway is regulated by cirsilineol. While the precise molecular mechanisms through which cirsilineol inhibits NF-κB pathway need further investigation, understanding these mechanisms would provide valuable insights into the compound's mode of action and aid in optimizing its potential therapeutic applications.

CONCLUSION

Cirsilineol inhibits cell proliferation, induces cell cycle arrest, and suppresses migration and invasion in endometriotic epithelial cells by regulating NF-κB pathway. Thus, these findings indicate that cirsilineol is a promising therapeutic candidate for the management of endometriosis.

DECLARATIONS

Acknowledgements

This work was supported by Chinese medicine research topic of Heilongjiang Provincial Chinese Medicine Bureau (Grant no. ZHY2023-007).

Funding

None provided.

Ethical approval

None provided.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. Xumeng Gu and Wenzhang Wu designed the study and carried them out; Xumeng Gu, Tianchan Zhang, Tongtong Liu and Huifang Cong supervised the data collection, analyzed and interpreted the data, and Xumeng Gu and Wenzhang Wu prepared the manuscript for publication and reviewed the draft of the manuscript. All authors read and approved the manuscript.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under
the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/resolution), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

REFERENCES


